Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG9588 in Renal Allograft Transplantation
NCT00001857Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 1999
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruplizumab in kidney transplant rejection (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Incidence of acute rejection episodes at 42 months, Incidence of chronic rejection episodes at 42 months and 1 more. Started May 1999; status: completed.
02
Drugs
ruplizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00001857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001857.